fenfluramine has been researched along with Diabetes Mellitus, Type 2 in 54 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 7.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "In the patients with obesity and NIDDM, the fasting and postprandial blood glucose and glycosylated haemoglobin were also highly significantly reduced." | 6.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "Dexfenfluramine aids weight loss and improves glycemic control in obese Chinese NIDDM patients over a 3- to 6-month period." | 5.08 | Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. ( Chan, JC; Chow, CC; Cockram, CS; Ko, GT; Tsang, LW; Yeung, VT, 1997) |
| "To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period." | 5.07 | Dexfenfluramine in type II diabetes: effect on weight and diabetes control. ( Davis, TM; Findlater, P; Stein, GR; Stewart, GO, 1993) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Dexfenfluramine has been shown to promote weight loss in overweight people." | 5.07 | The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. ( Molyneaux, LM; Overland, JE; Willey, KA; Yue, DK, 1992) |
| " Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
| "We have examined the effect of chronic (21 days) oral administration of the serotoninergic anorectic drug d-fenfluramine (5 mg/kg) in a rat model of non-insulin-dependent diabetes (without obesity), as induced by injection of a low dose (45 mg/kg) of streptozotocin at 6 weeks, and characterized by marked hyperglycaemia and hepatic and peripheral insulin resistance." | 3.69 | d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats. ( Bailbé, D; Picarel-Blanchot, F; Portha, B, 1994) |
| "The authors have evaluated the efficacy of d-fenfluramine, a serotoninergic anorectic drug, in 42 obese patients with non-insulin-dependent diabetes mellitus (NIDDM) who not very responded only to the hypocaloric diet or associated therapy with oral hypoglycemic agents." | 3.69 | [The treatment of the obese non-insulin-dependent patient with d-fenfluramine]. ( Coco, MP; Daniele, E, 1996) |
| "To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfenfluramine in men with non-insulin dependent diabetes mellitus (NIDDM)." | 3.69 | Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. ( Clark, ML; Hockaday, TD; Marks, SJ; Moore, NR; Pointon, JJ; Ryley, NG; Strauss, BJ, 1997) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 3.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "Treatment with benfluorex was well tolerated; 39% of these patients reported one or more emergent adverse events (compared to 38% on placebo and 43% on metformin) and only two patients suffered a treatment-related, serious adverse event." | 2.71 | Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. ( Del Prato, S; Erkelens, DW; Leutenegger, M, 2003) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| "Dexfenfluramine was most effective in the short term, behavioural therapy useful long term but only in those who remained within the group; home visits offered no advantage." | 2.68 | The comparison of four weight reduction strategies aimed at overweight diabetic patients. ( Jung, RT; Leese, GP; Manning, RM; Newton, RW, 1995) |
| "In the patients with obesity and NIDDM, the fasting and postprandial blood glucose and glycosylated haemoglobin were also highly significantly reduced." | 2.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "Benfluorex is a hypolipidaemic agent with biguanide-like properties." | 2.67 | Mechanism(s) of the blood glucose lowering action of benfluorex. ( Da Tos, V; De Biasi, L; Del Prato, S; Dorella, M; Marescotti, MC; Riccio, A; Tiengo, A; Vigili de Kreutzenberg, S, 1993) |
| "Benfluorex hydrochloride has known lipid- and glucose-lowering effects." | 2.67 | Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Benfluorex is a hypolipidemic agent with biguanide-like properties." | 2.67 | [Mechanisms of hypoglycemic action of benfluorex]. ( Da Tos, V; Del Prato, S; Dorella, M; Riccio, A; Vigili de Kreutzenberg, S, 1992) |
| "Benfluorex has been reported to decrease blood glucose in different dismetabolic conditions, particularly in noninsulin-dependent diabetic (NIDD) patients, but the mechanism of this effect is poorly known." | 2.67 | Benfluorex and blood glucose control in non insulin-dependent diabetic patients. ( Boine, L; Cavallo-Perin, P; Cobelli, C; Estivi, P; Galletti, R; Pacini, G; Pagano, G, 1991) |
| "Insulin resistance is one of the cardinal pathophysiological components of the metabolic syndrome, type 2 diabetes, and frequently co-exists with essential hypertension." | 2.40 | Insulin resistance: site of the primary defect or how the current and the emerging therapies work. ( Caro, JF; Kolaczynski, JW, 1998) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.26) | 18.7374 |
| 1990's | 38 (70.37) | 18.2507 |
| 2000's | 5 (9.26) | 29.6817 |
| 2010's | 5 (9.26) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Göldner, V | 1 |
| Karst, U | 1 |
| Moulin, P | 3 |
| André, M | 2 |
| Alawi, H | 2 |
| Dos Santos, LC | 2 |
| Khalid, AK | 2 |
| Koev, D | 2 |
| Moore, R | 2 |
| Serban, V | 2 |
| Picandet, B | 3 |
| Francillard, M | 2 |
| Benkimoun, P | 1 |
| Nau, JY | 1 |
| Vincent, L | 1 |
| Guardiola, B | 1 |
| Tsouderos, Y | 1 |
| Canet, E | 1 |
| Derumeaux, G | 1 |
| Ernande, L | 1 |
| Serusclat, A | 1 |
| Servan, E | 1 |
| Bruckert, E | 1 |
| Rousset, H | 1 |
| Senn, S | 1 |
| Van Gaal, L | 1 |
| Gavini, F | 1 |
| Watson, R | 1 |
| Del Prato, S | 3 |
| Erkelens, DW | 3 |
| Leutenegger, M | 2 |
| Boulé, NG | 1 |
| Chaput, JP | 1 |
| Doucet, E | 1 |
| Richard, D | 1 |
| Després, JP | 1 |
| Bouchard, C | 1 |
| Tremblay, A | 1 |
| Verdy, M | 4 |
| Charbonneau, L | 1 |
| Verdy, I | 3 |
| Belanger, R | 1 |
| Bolte, E | 1 |
| Chiasson, JL | 3 |
| Hamet, P | 2 |
| Manning, RM | 1 |
| Jung, RT | 1 |
| Leese, GP | 1 |
| Newton, RW | 1 |
| Picarel-Blanchot, F | 1 |
| Bailbé, D | 3 |
| Portha, B | 3 |
| Greco, AV | 1 |
| Mingrone, G | 1 |
| Capristo, E | 1 |
| De Gaetano, A | 1 |
| Ghirlanda, G | 1 |
| Castagneto, M | 1 |
| Proietto, J | 1 |
| Thorburn, AW | 1 |
| Fabris, S | 1 |
| Harrison, LC | 1 |
| Walsh, JP | 1 |
| Davis, TM | 2 |
| Stewart, GO | 2 |
| Stein, GR | 2 |
| Findlater, P | 2 |
| Riccio, A | 2 |
| Vigili de Kreutzenberg, S | 2 |
| Dorella, M | 2 |
| Da Tos, V | 2 |
| De Biasi, L | 1 |
| Marescotti, MC | 1 |
| Tiengo, A | 1 |
| De Feo, P | 1 |
| Lavielle, R | 1 |
| De Gregoris, P | 1 |
| Bolli, GB | 1 |
| Bianchi, R | 2 |
| Bongers, V | 2 |
| Bravenboer, B | 2 |
| Brindley, DN | 2 |
| Serradas, P | 2 |
| Blondel, O | 2 |
| Picarel, F | 1 |
| Storlien, LH | 1 |
| Pan, DA | 1 |
| Kusunoki, M | 1 |
| Cooney, GJ | 1 |
| Daniele, E | 1 |
| Coco, MP | 1 |
| Marks, SJ | 2 |
| Moore, NR | 2 |
| Clark, ML | 2 |
| Strauss, BJ | 2 |
| Hockaday, TD | 2 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| Ryley, NG | 1 |
| Pointon, JJ | 1 |
| Chow, CC | 1 |
| Ko, GT | 1 |
| Tsang, LW | 1 |
| Yeung, VT | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Enzi, G | 1 |
| DeMeo, MT | 1 |
| Mobarhan, S | 1 |
| Mikolaitis, S | 1 |
| Kazi, N | 1 |
| Ravel, D | 1 |
| Redmon, B | 1 |
| Raatz, S | 1 |
| Bantle, JP | 3 |
| Marinella, MA | 1 |
| Berrettoni, BA | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 2 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
| Drain, P | 1 |
| Kolaczynski, JW | 1 |
| Caro, JF | 1 |
| Redmon, JB | 2 |
| Raatz, SK | 2 |
| Kwong, CA | 2 |
| Swanson, JE | 2 |
| Thomas, W | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Rothman, RB | 1 |
| Willey, KA | 1 |
| Molyneaux, LM | 1 |
| Overland, JE | 1 |
| Yue, DK | 1 |
| Balabolkin, MI | 1 |
| Novikova, OM | 1 |
| Levitskaia, ZI | 1 |
| Meinders, AE | 1 |
| Scheen, AJ | 1 |
| Paolisso, G | 1 |
| Salvatore, T | 1 |
| Lefèbvre, PJ | 1 |
| Cavallo-Perin, P | 1 |
| Estivi, P | 1 |
| Boine, L | 1 |
| Galletti, R | 1 |
| Pacini, G | 1 |
| Cobelli, C | 1 |
| Pagano, G | 1 |
| Pestell, RG | 1 |
| Crock, PA | 1 |
| Ward, GM | 1 |
| Alford, FP | 1 |
| Best, JD | 1 |
| Beauchamp, Y | 1 |
| Bissonnette, J | 1 |
| Farah-Lajoie, C | 1 |
| Graham, S | 1 |
| Guay, JP | 1 |
| Kingsley, N | 1 |
| Perrier, A | 1 |
| Rochon, JL | 1 |
| Treymann, D | 1 |
8 reviews available for fenfluramine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
Effects of benfluorex on in vivo patterns of insulin resistance induced by diets rich in fat or fructose.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fa | 1993 |
[Benfluorex (Mediator) and non-insulin-dependent diabetes].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hypolipidemic Agents; Insul | 1997 |
[Benfluorex (Mediator): non-insulin-dependent diabetes and hypertriglyceridemia].
Topics: Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hypertriglyceridemia | 1998 |
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypog | 1998 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human | 1990 |
28 trials available for fenfluramine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18 to 34-week, open-label, extension period.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenf | 2009 |
Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Fenfluramine; Glycated Hemoglobin; Heart | 2012 |
Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.
Topics: Appetite Depressants; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female | 2003 |
Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fema | 2006 |
Glucose homeostasis predicts weight gain: prospective and clinical evidence.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fenfluramine; Glucose Tolerance Test; | 2008 |
Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.
Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Meth | 1983 |
The comparison of four weight reduction strategies aimed at overweight diabetic patients.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Female; Fenfluramine; Huma | 1995 |
Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Central Nervous System; Diabetes Mellitus, Type 2; Female; Fenfluramine; | 1994 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Diabetes Mellitus, Type 2; Fenfluramine; Glycated Hemoglobin; Humans; Weight Loss | 1994 |
Mechanism(s) of the blood glucose lowering action of benfluorex.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; | 1993 |
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Fenfluram | 1993 |
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; | 1993 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 1993 |
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes Mellitu | 1997 |
[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Appetite Depressants; Diabetes Mellitus; Diabetes Mel | 1997 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fem | 2000 |
[Mechanisms of hypoglycemic action of benfluorex].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Fenfluramine; Fructosamine; Glycated He | 1992 |
[Antidiabetic efficacy of benfluorex. Clinical data].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypolipidemic A | 1992 |
The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1992 |
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1991 |
Benfluorex and blood glucose control in non insulin-dependent diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenfluramine; Humans; Hypolip | 1991 |
Fenfluramine increases insulin action in patients with NIDDM.
Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fem | 1989 |
Hypoglycemic effect of fenfluramine in insulin-treated diabetics.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1986 |
18 other studies available for fenfluramine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Benfluorex metabolism complemented by electrochemistry-mass spectrometry.
Topics: Diabetes Mellitus, Type 2; Electrochemistry; Fenfluramine; Humans; Norfenfluramine; Tandem Mass Spec | 2023 |
French doctors demand to know why drug stayed on the market for so long.
Topics: Attitude of Health Personnel; Diabetes Mellitus, Type 2; Fenfluramine; France; Humans; Hypoglycemic | 2010 |
[What were the indications for the Mediator in 1979?].
Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases | 2011 |
Mediator: who's to blame?
Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Drug Industry; Fenfluramine; France; Glycated Hemog | 2011 |
European legislators tighten rules on drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Diabetes Mellitus, Type 2; Europe; Fe | 2012 |
[Speed of action of fenfluramine on blood glucose levels].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Middle Aged | 1983 |
d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Experimental; | 1994 |
Insulin resistance, hyperinsulinemia and diabetes--contribution of benfluorex. Prague, 11 September 1992. Symposium proceedings.
Topics: Animals; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperinsulinism; Hypoglycemic Agents; Insu | 1993 |
Effect of benfluorex on insulin secretion and insulin action in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fenfluramine; Gl | 1993 |
Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Fenflura | 1993 |
[The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
Topics: Adult; Aged; Appetite Depressants; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr | 1996 |
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
Topics: Adipose Tissue; Adult; Appetite Depressants; Body Composition; Body Constitution; Body Mass Index; C | 1996 |
Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
Topics: Adult; Biopsy; Confidence Intervals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Liver; Fema | 1997 |
Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases.
Topics: Adult; Aged; Appetite Depressants; Diabetes Mellitus, Type 2; Diet, Reducing; Fatty Liver; Female; F | 1997 |
Valvular heart disease associated with fenfluramine-phentermine.
Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fenfluramine; Heart Valv | 1997 |
Digital necrosis associated with dexfenfluramine.
Topics: Adult; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; Fingers; Humans; Male; Necrosi | 1997 |
[Effects of ponderal on the state of carbohydrate metabolism and insulin secretion in type 2 diabetes mellitus].
Topics: Adult; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; | 1991 |
[Treatment of type II diabetes with fenfluramine. Usefulness in general practice].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Family Practice; Female; Fenfluramine; Humans; Male; Middle | 1986 |